These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

461 related items for PubMed ID: 17049798

  • 1. Meropenem and imipenem activity against Pseudomonas aeruginosa isolates from the MYSTIC Program.
    Turner PJ.
    Diagn Microbiol Infect Dis; 2006 Nov; 56(3):341-4. PubMed ID: 17049798
    [Abstract] [Full Text] [Related]

  • 2. Activity of meropenem and comparators against Pseudomonas aeruginosa and Acinetobacter spp. isolated in the MYSTIC Program, 2002-2004.
    Unal S, Garcia-Rodriguez JA.
    Diagn Microbiol Infect Dis; 2005 Dec; 53(4):265-71. PubMed ID: 16360550
    [Abstract] [Full Text] [Related]

  • 3. MYSTIC Europe 2007: activity of meropenem and other broad-spectrum agents against nosocomial isolates.
    Turner PJ.
    Diagn Microbiol Infect Dis; 2009 Feb; 63(2):217-22. PubMed ID: 19070453
    [Abstract] [Full Text] [Related]

  • 4. Contemporary activity of meropenem and comparator broad-spectrum agents: MYSTIC program report from the United States component (2005).
    Rhomberg PR, Jones RN.
    Diagn Microbiol Infect Dis; 2007 Feb; 57(2):207-15. PubMed ID: 16949243
    [Abstract] [Full Text] [Related]

  • 5. Meropenem activity against European isolates: report on the MYSTIC (Meropenem Yearly Susceptibility Test Information Collection) 2006 results.
    Turner PJ.
    Diagn Microbiol Infect Dis; 2008 Feb; 60(2):185-92. PubMed ID: 17945455
    [Abstract] [Full Text] [Related]

  • 6. Role of outer membrane protein OprD and penicillin-binding proteins in resistance of Pseudomonas aeruginosa to imipenem and meropenem.
    Farra A, Islam S, Strålfors A, Sörberg M, Wretlind B.
    Int J Antimicrob Agents; 2008 May; 31(5):427-33. PubMed ID: 18375104
    [Abstract] [Full Text] [Related]

  • 7. Antimicrobial susceptibility pattern comparisons among intensive care unit and general ward Gram-negative isolates from the Meropenem Yearly Susceptibility Test Information Collection Program (USA).
    Rhomberg PR, Fritsche TR, Sader HS, Jones RN.
    Diagn Microbiol Infect Dis; 2006 Sep; 56(1):57-62. PubMed ID: 16631338
    [Abstract] [Full Text] [Related]

  • 8. Susceptibility of Pseudomonas aeruginosa clinical isolates in Japan to doripenem and other antipseudomonal agents.
    Fujimura T, Anan N, Sugimori G, Watanabe T, Jinushi Y, Yoshida I, Yamano Y.
    Int J Antimicrob Agents; 2009 Dec; 34(6):523-8. PubMed ID: 19748767
    [Abstract] [Full Text] [Related]

  • 9. Predicting doripenem susceptibility based on meropenem and imipenem interpretation for Pseudomonas aeruginosa.
    Hagihara M, Kuti JL, Nicolau DP.
    Diagn Microbiol Infect Dis; 2012 Mar; 72(3):258-62. PubMed ID: 22209563
    [Abstract] [Full Text] [Related]

  • 10. Summary trends for the Meropenem Yearly Susceptibility Test Information Collection Program: a 10-year experience in the United States (1999-2008).
    Rhomberg PR, Jones RN.
    Diagn Microbiol Infect Dis; 2009 Dec; 65(4):414-26. PubMed ID: 19833471
    [Abstract] [Full Text] [Related]

  • 11. Comparative in vivo efficacy of meropenem, imipenem, and cefepime against Pseudomonas aeruginosa expressing MexA-MexB-OprM efflux pumps.
    Ong CT, Tessier PR, Li C, Nightingale CH, Nicolau DP.
    Diagn Microbiol Infect Dis; 2007 Feb; 57(2):153-61. PubMed ID: 16930925
    [Abstract] [Full Text] [Related]

  • 12. An overview of the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Program: 1997-2004.
    Jones RN, Mendes C, Turner PJ, Masterton R.
    Diagn Microbiol Infect Dis; 2005 Dec; 53(4):247-56. PubMed ID: 16360548
    [Abstract] [Full Text] [Related]

  • 13. Increase of imipenem resistance among Pseudomonas aeruginosa isolates from a Polish paediatric hospital (1993-2002).
    Patzer JA, Dzierzanowska D.
    Int J Antimicrob Agents; 2007 Feb; 29(2):153-8. PubMed ID: 17157481
    [Abstract] [Full Text] [Related]

  • 14. Determination of epidemic clonality among multidrug-resistant strains of Acinetobacter spp. and Pseudomonas aeruginosa in the MYSTIC Programme (USA, 1999-2003).
    Jones RN, Deshpande L, Fritsche TR, Sader HS.
    Diagn Microbiol Infect Dis; 2004 Jul; 49(3):211-6. PubMed ID: 15246512
    [Abstract] [Full Text] [Related]

  • 15. Antibiotic resistance surveillance over a 4-year period (2000-2003) in Turkey: results of the MYSTIC Program.
    Korten V, Ulusoy S, Zarakolu P, Mete B, Turkish MYSTIC Study Group.
    Diagn Microbiol Infect Dis; 2007 Dec; 59(4):453-7. PubMed ID: 17888609
    [Abstract] [Full Text] [Related]

  • 16. Comparative Activity of Carbapenem Testing (COMPACT) study in Germany.
    Valenza G, Seifert H, Decker-Burgard S, Laeuffer J, Morrissey I, Mutters R, COMPACT Germany Study Group.
    Int J Antimicrob Agents; 2012 Mar; 39(3):255-8. PubMed ID: 22230334
    [Abstract] [Full Text] [Related]

  • 17. Susceptibility of bacterial isolates from Turkey--a report from the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Program.
    Eraksoy H, Basustaoglu A, Korten V, Kurt H, Ozturk R, Ulusoy S, Yaman A, Yuce A, Zarakolu P, Turkish MYSTIC Study Group.
    J Chemother; 2007 Dec; 19(6):650-7. PubMed ID: 18230545
    [Abstract] [Full Text] [Related]

  • 18. Optimising antibiotic dosing regimens based on pharmacodynamic target attainment against Pseudomonas aeruginosa collected in Hungarian hospitals.
    Ludwig E, Konkoly-Thege M, Kuti JL, Nicolau DP.
    Int J Antimicrob Agents; 2006 Nov; 28(5):433-8. PubMed ID: 17046212
    [Abstract] [Full Text] [Related]

  • 19. The Meropenem Yearly Susceptibility Test Information Collection antimicrobial susceptibility program in Spain: a 5-year analysis.
    Pascual A, Perea E, Alvarez M, Casal M, Garcia de Lomas J, Garcia Rodríguez JA, Martin R, Soria G, Zapardiel J, Spanish MYSTIC group.
    Diagn Microbiol Infect Dis; 2007 Feb; 57(2):195-200. PubMed ID: 17052882
    [Abstract] [Full Text] [Related]

  • 20. Detection of outer membrane porin protein, an imipenem influx channel, in Pseudomonas aeruginosa clinical isolates.
    Naenna P, Noisumdaeng P, Pongpech P, Tribuddharat C.
    Southeast Asian J Trop Med Public Health; 2010 May; 41(3):614-24. PubMed ID: 20578550
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.